LONDON (Alliance News) - Physiomics PLC on Tuesday said it has signed a contract with a new specialty pharmaceutical customer to perform PK/PD modelling analysis in a project related to drugs used to treat pain.
The biology company said the project will be performed on a fee-for-service basis.
"We are extremely pleased to have added another new customer for a fee-paying commercial project. We are also happy to have expanded our services beyond oncology into treating pain. We hope to gain further business with this customer and similar clients in the future," Chief Executive Mark Chadwick said in a statement.
Shares in Physiomics were trading up 14% at 0.0399 pence following the announcement Tuesday morning.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Physiomics (PYC)